Go to the list of all blogs
Allana's Avatar
published in Blogs
Sep 24, 2026
AEHR and ONTO: Contrasting Paths in the AI Semiconductor Equipment Space

AEHR and ONTO: Contrasting Paths in the AI Semiconductor Equipment Space

Key Takeaways

  • AEHR is a smaller, higher-growth semiconductor test and burn-in specialist that has surged sharply in recent months on AI-related demand, trading at a premium valuation.
  • ONTO is a larger, profitable process-control leader with a record backlog and stronger, more diversified revenue base.
  • Both stocks benefit from AI, advanced packaging, and high-bandwidth memory (HBM) trends, but they occupy different positions in the semiconductor equipment value chain.
  • AEHR is a turnaround story pivoting toward AI processors and silicon photonics; ONTO is a more established compounder with demonstrated profitability and cash generation.
  • Relative performance and market positioning differ materially, with AEHR showing greater volatility and ONTO offering comparatively more earnings stability.

Why These Two Names Matter Right Now

Investors following the artificial intelligence-driven semiconductor equipment cycle often compare specialist test providers with diversified process-control companies. This comparison looks at AEHR (Aehr Test Systems) and ONTO (Onto Innovation), two companies with overlapping exposure to AI processors, advanced packaging, and HBM yet very different business models and risk profiles. Growth-oriented traders may focus on AEHR’s rapid momentum and premium valuation, while those seeking profitability and scale may prefer ONTO’s established position. I also checked this using Tickeron’s AI Screener to see how the stocks line up against industry peers. Understanding the differences in relative performance, market positioning, and catalysts helps clarify how each might fit within a diversified semiconductor portfolio.

AEHR’s Momentum and Business Shift

Aehr Test Systems, based in Fremont, California, supplies test and burn-in systems used to screen and stabilize semiconductor devices at the wafer level, in singulated die, and at the package level. In recent weeks, AEHR has been among the sector’s stronger performers, with shares climbing as investors repriced its growth outlook. The company reported record fiscal fourth-quarter bookings and a roughly $100 million effective backlog, while guiding to a significant step-up in fiscal 2027 revenue. Sentiment has been supported by a shift in revenue mix toward AI processors, silicon photonics, and power semiconductors, moving away from the electric-vehicle silicon carbide demand that previously dominated. The company also holds a strengthened cash position following an equity offering. This momentum has left the stock trading at a steep forward-sales multiple relative to its own history and industry peers.

ONTO’s Scale and Recent Results

Onto Innovation, headquartered in Wilmington, Massachusetts, provides process-control systems spanning metrology, inspection, and lithography used across the semiconductor value chain, including advanced packaging and leading-edge chip manufacturing. ONTO has posted strong recent market activity, supported by record quarterly revenue, a gross margin that expanded to roughly 57%, and a backlog exceeding $1.1 billion. Demand has been led by advanced-node metrology and inspection platforms such as the Dragonfly and Atlas families, with particular strength in 2.5D logic packaging and HBM. The company raised its second-half growth outlook and holds nearly $1.9 billion in cash and short-term investments. As with AEHR, elevated valuation multiples and customer concentration remain considerations, but ONTO’s scale, profitability, and diversified revenue base differentiate its risk profile.

Side-by-Side Comparison

The two companies serve different functions within the semiconductor supply chain. AEHR focuses on reliability screening through test and burn-in, a role that becomes more critical as AI processors and silicon photonics ramp into production. ONTO focuses on process control—measuring, inspecting, and analyzing wafers and packages to improve yield—giving it broad exposure to advanced nodes, memory, and packaging. In terms of scale, ONTO generates far higher revenue and is solidly profitable, while AEHR is transitioning from a period of losses toward a projected rebound. Growth drivers differ in intensity: AEHR’s forward guidance implies a very large year-over-year revenue increase from a small base, whereas ONTO’s growth, though strong, is more moderate in percentage terms. Risk profiles also diverge—AEHR carries higher volatility and a richer valuation multiple, while ONTO’s principal sensitivities include customer concentration and memory-cycle timing. Market sentiment toward both remains positive, but for different reasons.

Where Tickeron’s AI Assessment Points

Based on observable factors, Tickeron’s AI would likely tilt toward ONTO on a relative basis. Its consistent trend, demonstrated profitability, record backlog, and expanding margins suggest a more stable and lower-risk trajectory than AEHR’s higher-volatility, higher-multiple turnaround. That said, AEHR offers potentially greater upside if its AI and silicon-photonics bookings translate into sustained revenue growth. The AI-driven assessment leans on trend consistency and stability rather than raw momentum, which favors ONTO while acknowledging that AEHR’s catalysts could narrow the gap under favorable execution. I also looked at Tickeron’s AI Trend Prediction Engine for additional context on both names.

Exploring Tickeron’s Trending AI Robots

When reviewing momentum names such as these, I often browse Tickeron’s Trending AI Robots page to see which automated strategies are performing well in the current environment. The section highlights a curated selection of AI trading bots, each with its own style, timeframe, and performance statistics. This can provide a data-driven perspective on navigating stocks like AEHR and ONTO without relying solely on manual analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AEHR, ONTO

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for AEHR turns positive, indicating new upward trend

AEHR saw its Momentum Indicator move above the 0 level on September 10, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 77 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for AEHR just turned positive on September 18, 2026. Looking at past instances where AEHR's MACD turned positive, the stock continued to rise in 31 of 37 cases over the following month. The odds of a continued upward trend are 84%.

AEHR moved above its 50-day moving average on September 18, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +7.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where AEHR advanced for three days, in 246 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

Bearish Trend Analysis

The 10-day RSI Indicator for AEHR moved out of overbought territory on August 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 35 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The 10-day moving average for AEHR crossed bearishly below the 50-day moving average on September 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AEHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock slightly better than average.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.493) is normal, around the industry mean (8.083). P/E Ratio (19.449) is within average values for comparable stocks, (165.446). Projected Growth (PEG Ratio) (0.916) is also within normal values, averaging (0.821). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (51.813) is also within normal values, averaging (27.897).

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Lam Research Corp (NASDAQ:LRCX), Applied Materials (NASDAQ:AMAT), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 62.46B. The market cap for tickers in the group ranges from 326.86K to 666.49B. ASMLF holds the highest valuation in this group at 666.49B. The lowest valued company is AVSR at 326.86K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 5%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 25%. COHU experienced the highest price growth at 26%, while SMTK experienced the biggest fall at -29%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 35
Price Growth Rating: 48
SMR Rating: 71
Profit Risk Rating: 61
Seasonality Score: -31 (-100 ... +100)
View a ticker or compare two or three
AEHR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of burn-in and test equipment for semiconductor manufacturing

Industry ElectronicProductionEquipment

Industry
Electronic Production Equipment
Address
400 Kato Terrace
Phone
+1 510 623-9400
Employees
138
Web
https://www.aehr.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.
AEHR and ONTO: Contrasting Paths in the AI Semiconductor Equipment Space